S100A9 and hepatocellular carcinoma: To verify whether S100A9 serves as a potential therapeutic target for HCC, we constructed HCC patient‐derived xenograft (PDX) models in nude mice and utilized siRNA or Tas to target S100A9 (Figure 6F,G).